Chondroblastoma is an uncommon and benign tumor which produces chondroids. It develops towards the ends of the long bones and represents under 1% of all bone cancers. Chondroblastoma ypically develops in the apophyses or epiphyses of individuals with underdeveloped skeletons.
The word chondroblastoma was coined due to the underdeveloped chondroid cells and the incompletely formed matrix associated with this condition. Both malignant and benign etiologies need to be examined when diagnosing these neoplasms, which are typically found in the long bones.
Three sites which are most commonly affected by this condition are the proximal femur, distal femur, and the proximal humerus. Surgical treatment is the only preferred method of treatment for chondroblastomas. In general, the prognosis for chondroblastoma is favorable, and patients frequently experience complete remission after surgical therapy.
Epidemiology
Chrondroblastoma is a rare condition, merely responsible for just under 1% of all bone tumors. The mean age of diagnosis is between 19-23 years, and most cases are of individuals in their 20s or 30s. Males are twice as likely to be affected.
Chrondroblastomas always only affect one bone, and their incidence is much higher in long bones. This condition rarely affects the bones of the feet or hands, or any flat bones. Common regions affected include the distal and proximal femur, proximal humerus, and the proximal tibia.
Anatomy
Pathophysiology
Despite the presence of several studies, chondroblastoma histogenesis remains unresolved. Cartialge epiphyseal cartilage cells or germ cells could be the cells that this condition originates from.
Another hypothesized etiological site is a tendon sheath synovial cell or multipotent mesenchymal cell.
Etiology
Genetics
Analysing flow cytometric studies demonstrates that the majority of chondroblastomas have a diploid structure and have modest proliferation percentages. Clonal anomalies have been reported in fourteen chondroblastomas.
Unbalanced and balanced rearrangements of chromosomes 8 and 5 seem the most prevalent. Recent research has revealed that chondroblastomas contain unique genetic mutations that code for H3.3 histone.
In chondroblastomas, the H3F3A gene is not commonly mutated as H3F3A. Chondroblastoma-specific antibodies against H3F3 K36M mutation have been identified through research.
Prognostic Factors
Untreated chondroblastomas do not experience any regression. Its recurrence rates range between 8.3% to 21.4%. These percentages may be attributed to residual tumor material post-surgery. Inadequate surgery, hip and pelvic location, young age, and the presence of aneurysmal bone cysts are factors which enhance the likelihood of recurrence.
Chondroblastomas with a benign histopathology rarely causes pulmonary metastases. Such metastases are also clinically non-progressive and can be treated with surgical resection or simple observation. In very rare instances, a chondroblastoma can evolve into a malignant tumor. There are no consistent histological characteristics that can predict a more aggressive disposition.
Clinical History
Physical Examination
Age group
Associated comorbidity
Associated activity
Acuity of presentation
Differential Diagnoses
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
by Stage
by Modality
Chemotherapy
Radiation Therapy
Surgical Interventions
Hormone Therapy
Immunotherapy
Hyperthermia
Photodynamic Therapy
Stem Cell Transplant
Targeted Therapy
Palliative Care
Medication
Future Trends
Media Gallary
References
https://pubmed.ncbi.nlm.nih.gov/3978565/
https://www.ncbi.nlm.nih.gov/books/NBK536947/
News
Female Surgeons in NHS Face Rampant Sexual Harassment
Posted on
News
Gene Therapy Promises Restoration of Motor Function
Posted on
News
Ultra-Processed Foods Linked to Elevated Depression Risk in Women
Posted on
News
Research Reveals How Language Shapes Social Memory in the Brain
Chondroblastoma is an uncommon and benign tumor which produces chondroids. It develops towards the ends of the long bones and represents under 1% of all bone cancers. Chondroblastoma ypically develops in the apophyses or epiphyses of individuals with underdeveloped skeletons.
The word chondroblastoma was coined due to the underdeveloped chondroid cells and the incompletely formed matrix associated with this condition. Both malignant and benign etiologies need to be examined when diagnosing these neoplasms, which are typically found in the long bones.
Three sites which are most commonly affected by this condition are the proximal femur, distal femur, and the proximal humerus. Surgical treatment is the only preferred method of treatment for chondroblastomas. In general, the prognosis for chondroblastoma is favorable, and patients frequently experience complete remission after surgical therapy.
Chrondroblastoma is a rare condition, merely responsible for just under 1% of all bone tumors. The mean age of diagnosis is between 19-23 years, and most cases are of individuals in their 20s or 30s. Males are twice as likely to be affected.
Chrondroblastomas always only affect one bone, and their incidence is much higher in long bones. This condition rarely affects the bones of the feet or hands, or any flat bones. Common regions affected include the distal and proximal femur, proximal humerus, and the proximal tibia.
Despite the presence of several studies, chondroblastoma histogenesis remains unresolved. Cartialge epiphyseal cartilage cells or germ cells could be the cells that this condition originates from.
Another hypothesized etiological site is a tendon sheath synovial cell or multipotent mesenchymal cell.
Analysing flow cytometric studies demonstrates that the majority of chondroblastomas have a diploid structure and have modest proliferation percentages. Clonal anomalies have been reported in fourteen chondroblastomas.
Unbalanced and balanced rearrangements of chromosomes 8 and 5 seem the most prevalent. Recent research has revealed that chondroblastomas contain unique genetic mutations that code for H3.3 histone.
In chondroblastomas, the H3F3A gene is not commonly mutated as H3F3A. Chondroblastoma-specific antibodies against H3F3 K36M mutation have been identified through research.
Untreated chondroblastomas do not experience any regression. Its recurrence rates range between 8.3% to 21.4%. These percentages may be attributed to residual tumor material post-surgery. Inadequate surgery, hip and pelvic location, young age, and the presence of aneurysmal bone cysts are factors which enhance the likelihood of recurrence.
Chondroblastomas with a benign histopathology rarely causes pulmonary metastases. Such metastases are also clinically non-progressive and can be treated with surgical resection or simple observation. In very rare instances, a chondroblastoma can evolve into a malignant tumor. There are no consistent histological characteristics that can predict a more aggressive disposition.
https://pubmed.ncbi.nlm.nih.gov/3978565/
https://www.ncbi.nlm.nih.gov/books/NBK536947/
medtigo
Chondroblastoma
Updated :
June 15, 2022
Chondroblastoma is an uncommon and benign tumor which produces chondroids. It develops towards the ends of the long bones and represents under 1% of all bone cancers. Chondroblastoma ypically develops in the apophyses or epiphyses of individuals with underdeveloped skeletons.
The word chondroblastoma was coined due to the underdeveloped chondroid cells and the incompletely formed matrix associated with this condition. Both malignant and benign etiologies need to be examined when diagnosing these neoplasms, which are typically found in the long bones.
Three sites which are most commonly affected by this condition are the proximal femur, distal femur, and the proximal humerus. Surgical treatment is the only preferred method of treatment for chondroblastomas. In general, the prognosis for chondroblastoma is favorable, and patients frequently experience complete remission after surgical therapy.
Chrondroblastoma is a rare condition, merely responsible for just under 1% of all bone tumors. The mean age of diagnosis is between 19-23 years, and most cases are of individuals in their 20s or 30s. Males are twice as likely to be affected.
Chrondroblastomas always only affect one bone, and their incidence is much higher in long bones. This condition rarely affects the bones of the feet or hands, or any flat bones. Common regions affected include the distal and proximal femur, proximal humerus, and the proximal tibia.
Despite the presence of several studies, chondroblastoma histogenesis remains unresolved. Cartialge epiphyseal cartilage cells or germ cells could be the cells that this condition originates from.
Another hypothesized etiological site is a tendon sheath synovial cell or multipotent mesenchymal cell.
Analysing flow cytometric studies demonstrates that the majority of chondroblastomas have a diploid structure and have modest proliferation percentages. Clonal anomalies have been reported in fourteen chondroblastomas.
Unbalanced and balanced rearrangements of chromosomes 8 and 5 seem the most prevalent. Recent research has revealed that chondroblastomas contain unique genetic mutations that code for H3.3 histone.
In chondroblastomas, the H3F3A gene is not commonly mutated as H3F3A. Chondroblastoma-specific antibodies against H3F3 K36M mutation have been identified through research.
Untreated chondroblastomas do not experience any regression. Its recurrence rates range between 8.3% to 21.4%. These percentages may be attributed to residual tumor material post-surgery. Inadequate surgery, hip and pelvic location, young age, and the presence of aneurysmal bone cysts are factors which enhance the likelihood of recurrence.
Chondroblastomas with a benign histopathology rarely causes pulmonary metastases. Such metastases are also clinically non-progressive and can be treated with surgical resection or simple observation. In very rare instances, a chondroblastoma can evolve into a malignant tumor. There are no consistent histological characteristics that can predict a more aggressive disposition.
https://pubmed.ncbi.nlm.nih.gov/3978565/
https://www.ncbi.nlm.nih.gov/books/NBK536947/
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
